Fitness & Wellness Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness & Wellness Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
CEL-SCI Announces Discovery of Novel Compound for the Treatment of Rheumatoid Arthritis
July 2nd, 2008
CEL-SCI Corporation (AMEX:CVM) announced the discovery of a novel peptide for the treatment of rheumatoid arthritis. This peptide, called CEL-2000, was tested in a well established animal model of rheumatoid arthritis and was compared to Enbrel(R), a leading treatment for people with rheumatoid arthritis. The tests showed that CEL-2000 is equivalent or possibly superior to Enbrel in slowing disease progression and lessening symptoms in mice. In addition, the vaccine has the potential to require fewer and smaller doses, be less toxic, more disease specific and much less invasive. The Company also believes that the drug could be attractive to patients who are not able to take or be...
Source: Fitness & Wellness Business Week (2008-07-02)
|
